Table 4 TEAEs occurring in ≥ 10% of patients and any grade 3/4 TEAEs*
Preferred term, n (%) | Ruxolitinib (N = 45) | |
|---|---|---|
TEAEs | Grade 3/4 TEAEs | |
Any | 42 (93.3) | 17 (37.8) |
Anemia | 12 (26.7) | 9 (20.0) |
Fatigue | 10 (22.2) | 0 |
Arthralgia | 9 (20.0) | 0 |
Nausea | 8 (17.8) | 0 |
Thrombocytopenia | 8 (17.8) | 1 (2.2) |
Dizziness | 7 (15.6) | 1 (2.2) |
Abdominal pain | 6 (13.3) | 0 |
Cough | 6 (13.3) | 0 |
Diarrhea | 6 (13.3) | 0 |
Edema peripheral | 6 (13.3) | 0 |
Muscle spasms | 6 (13.3) | 0 |
Pain in extremity | 6 (13.3) | 0 |
Back pain | 5 (11.1) | 0 |
Contusion | 5 (11.1) | 0 |
Umbilical hernia | 0 | 1 (2.2) |
Cholelithiasis | 0 | 1 (2.2) |
Dehydration | 0 | 1 (2.2) |
Blood creatine phosphokinase increased | 0 | 1 (2.2) |
Blood triglycerides increased | 0 | 1 (2.2) |
Lipase increased | 0 | 1 (2.2) |
Hyperkalemia | 0 | 1 (2.2) |
Hypermagnesemia | 0 | 1 (2.2) |
Myelodysplastic syndrome† | 0 | 1 (2.2) |